UCLA

CancerVax Launches $5 Million Funding Round

Retrieved on: 
Wednesday, April 3, 2024
CancerVax, Research, UCLA, Regulation, Cancer, Online shopping

Lehi, Utah, April 03, 2024 (GLOBE NEWSWIRE) -- CancerVax, Inc., developer of a breakthrough Universal Cancer Vaccine treatment that will use the body’s immune system to fight cancer, today announced that its Reg A+ offering has been qualified by the SEC allowing the Company to formally launch a funding round of up to $5 million.

Key Points: 
  • Lehi, Utah, April 03, 2024 (GLOBE NEWSWIRE) -- CancerVax, Inc., developer of a breakthrough Universal Cancer Vaccine treatment that will use the body’s immune system to fight cancer, today announced that its Reg A+ offering has been qualified by the SEC allowing the Company to formally launch a funding round of up to $5 million.
  • Proceeds from the SEC qualified Reg A+ offering will be used by the Company to continue work on its breakthrough cancer treatments.
  • CancerVax CEO, Byron Elton said, “We are very excited about the Company’s progress to date.
  • Thus far, we’ve raised $3.3 million of seed funding and plan to raise an additional $5 million to further the development of our novel cancer treatments.”
    The offering is available to the general public.

Lundquist Investigator Dr. Yoshihara Awarded $3 Million NIH R01 Grant for Diabetes Stem Cell Therapy Research

Retrieved on: 
Monday, April 1, 2024
TLI, Diabetes, Immunosuppression, Type 1, Research, Kidney, Hope, Doctor of Philosophy, NIH, Type 1 diabetes, NIDDK, Bangladesh Technical Education Board, UCLA, Digestive, Health, Cell, Organoid, Type 2, Medical device

This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.

Key Points: 
  • This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.
  • Insulin-dependent diabetes, including autoimmune Type 1 and stress-induced Type 2, presents a significant health burden, often necessitating lifelong insulin therapy and glucose monitoring.
  • Dr. Yoshihara's research focuses on the potential of human pluripotent stem cells (hPSCs) to create functional islet cells.
  • “Despite significant progress in stem cell-derived mini-organ technologies, we are still challenged by their functional immaturity and variability,” said Dr. Yoshihara.

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite St

Retrieved on: 
Monday, April 1, 2024
Lung cancer, Survival, Immunotherapy, Disease, Colorectal cancer, Progression-free survival, Medicine, Patient, Common, DNA, Aes, Cancer, Death, Doctor of Philosophy, Gritstone bio, MD, Kinetics, Induction chemotherapy, MSS, Circulating tumor DNA, VAF, Melanoma, PFS, Vaccine, Data, UCLA, Liver disease, Neoplasm, Pharmaceutical industry

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC). The randomized, controlled, open-label study is designed to quantify the clinical benefit of maintenance therapy with GRANITE (GRT-C901/GRT-R902) in combination with immune checkpoint blockade in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone. Overall progression free survival (PFS) data show an early trend in benefit for GRANITE patients (HR=0.82, [95% CI, 0.34-1.67]; 62% censored) and extended PFS benefit in high-risk patients (HR=0.52 [95% CI, 0.15-1.38]; 44% censored), in whom progression occurs faster. Circulating tumor DNA (ctDNA) analysis over several months of treatment shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis (molecular response as defined per protocol) did not demonstrate a difference between study arms. Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).

Key Points: 
  • Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).
  • “Today's preliminary Phase 2 results are highly encouraging and represent the first randomized trial evidence, albeit early, that a personalized neoantigen-directed vaccine can potentially drive efficacy in a metastatic ‘cold’ tumor.
  • Fortunately, long-term analysis demonstrates the expected correlation of ctDNA with clinical benefit and favors GRANITE patients.
  • This analysis was performed on 44 patients who received study treatment (control and GRANITE arms) and have available baseline ctDNA data.

Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Emory Healthcare, Sepsis, Conference, SAMI, Motivation, Clinical professor, Partnership, Patient, EAA, Mayo Clinic, Mortality, Septic shock, EDEN, University, Spectral, Intensive care unit, Critical care, PMX, AME Publishing Company, TSX, Clinical trial, Nephrology, ICU, FDA, UCLA, Baxter, Marketing, Economics, Hemoperfusion, Pharmaceutical industry

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.
  • Dr. John Kellum, Chief Medical Officer of Spectral Medical, stated, “We have witnessed robust enrollment activity to start 2024.
  • addition of two new trial sites in the fourth quarter – the Mayo Clinic and Emory Healthcare.
  • The Company concluded the 2023 year with cash of $2,952,000 compared to $8,414,000 cash on hand as of December 31, 2022.

Update - LiveOne (NASDAQ: LVO) Hosts Event Celebrating Women in the Entertainment Industry

Retrieved on: 
Wednesday, March 27, 2024
LVO, Entertainment, Female, Woman, Black, LiveOne, Warner Bros., Former, Music, LOS, Industry average, UCLA

LiveOne Team is over 40% Female, Outperforming Industry Average of 30%

Key Points: 
  • LiveOne Team is over 40% Female, Outperforming Industry Average of 30%
    LiveOne has Streamed Over 1K Top Female Artists, including Taylor Swift, Adele and Olivia Rodrigo, to 100M+ Viewers
    Fans Can Watch on Friday, March 29th at 4:00pm PT at https://www.liveone.com/live-events/event/women-in-entertainment
    LOS ANGELES, CA, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – LiveOne (NASDAQ: LVO), an award-winning, creator-first, music, entertainment and technology platform, announced today that it will stream the latest edition of LiveOne Presents: Celebrating Women in the Entertainment Industry.
  • In recognition of Women’s History Month, the event will include a performance by artist and songwriter, Tabi, who currently has a Top 50 song on urban radio with Josh Levi’s “Birthday Dance.”
    The event will also include a riveting panel discussion with female executives across the entertainment industry including:
    Carolyn Blackwood - Former COO, Warner Bros.
    Tiffany Naiman - Director of Music Industry Program, UCLA
    Samantha Maners - Artist Manager, blackbear
    Paige Kaplan - Entertainment Attorney, Greenberg Traurig
    LiveOne CEO Robert Ellin commented, “We are committed to equality and to increasing leadership opportunities for our all employees.
  • Embracing the perspectives and talents of a diverse collaborative on our leadership team isn't just a matter of fairness; it's a strategic imperative which strengthens our decision-making, fosters innovation, and drives sustainable success.”
    The performance and panel discussion will be streamed and available on LiveOne.com beginning Friday, March 29th at 4:00pm PT.

LiveOne (NASDAQ: LVO) Hosts Event Celebrating Women in the Entertainment Industry

Retrieved on: 
Wednesday, March 27, 2024
LVO, Entertainment, Female, Woman, Black, LiveOne, Warner Bros., Former, Music, LOS, Industry average, UCLA

LiveOne Team is over 40% Female, Outperforming Industry Average of 30%

Key Points: 
  • LiveOne Team is over 40% Female, Outperforming Industry Average of 30%
    LiveOne has Streamed Over 1K Top Female Artists, including Taylor Swift, Adele and Olivia Rodrigo, to 100M+ Viewers
    Fans Can Watch on Saturday, March 30th at 5:00pm PT on LiveOne.com
    LOS ANGELES, CA, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- LiveOne (NASDAQ: LVO), an award-winning, creator-first, music, entertainment and technology platform, announced today that it will stream the latest edition of LiveOne Presents: Celebrating Women in the Entertainment Industry.
  • In recognition of Women’s History Month, the event will include a performance by artist and songwriter, Tabi, who currently has a Top 50 song on urban radio with Josh Levi’s “Birthday Dance.”
    The event will also include a riveting panel discussion with female executives across the entertainment industry including:
    Carolyn Blackwood - Former COO, Warner Bros.
    Tiffany Naiman - Director of Music Industry Program, UCLA
    Samantha Maners - Artist Manager, blackbear
    Paige Kaplan - Entertainment Attorney, Greenberg Traurig
    LiveOne CEO Robert Ellin commented, “We are committed to equality and to increasing leadership opportunities for our all employees.
  • Embracing the perspectives and talents of a diverse collaborative on our leadership team isn't just a matter of fairness; it's a strategic imperative which strengthens our decision-making, fosters innovation, and drives sustainable success.”
    The performance and panel discussion will be streamed and available on LiveOne.com beginning Saturday, March 30th at 5:00pm PT.

American Lung Association and LUNGevity Foundation Announce $3 Million Research Partnership to Intercept Lung Cancer

Retrieved on: 
Tuesday, April 9, 2024
Boston University, Lung cancer, Enzyme, Disease, Health equity, Partnership, Patient, Research, Doctor of Philosophy, Helpline, MD, Quality of life, Protein, Master of Science, Clinical trial, Partial, Johnson & Johnson, Interventional oncology, American Lung Association, UCLA, Charity Navigator, Cancer, Estate (law), Medical imaging

In a collaborative effort to end this devastating disease, the American Lung Association and LUNGevity Foundation have joined forces to invest $3 million over the next three years in research aimed at intercepting lung cancer – catching precancerous cells and blocking them from turning into cancer cells.

Key Points: 
  • In a collaborative effort to end this devastating disease, the American Lung Association and LUNGevity Foundation have joined forces to invest $3 million over the next three years in research aimed at intercepting lung cancer – catching precancerous cells and blocking them from turning into cancer cells.
  • The partnership builds upon previous collaborations, including research funded by American Lung Association, LUNGevity Foundation and Stand Up To Cancer, which has yielded significant findings in lung cancer interception.
  • Through initiatives like the American Lung Association Research Institute Accelerator Program and the LUNGevity Early Lung Cancer Center , this partnership aims to accelerate progress in lung cancer interception research and pave the way for personalized treatments for patients.
  • LUNGevity, the nation's leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer.

Signature Resolution Welcomes Hon. Mitchell Beckloff (Ret.) to Panel of Neutrals

Retrieved on: 
Tuesday, April 9, 2024
Writ, Receiver, RET, Communication, Private sector, Court, Loyola Law School, Bruce's Beach, LOS, Superior court, UCLA

LOS ANGELES, April 8, 2024 /PRNewswire-PRWeb/ -- Signature Resolution, a leader in alternative dispute resolution, is pleased to announce the addition of Hon. Mitchell Beckloff (Ret.) to its panel of neutrals. After an illustrious judicial career that spanned over two decades on the Los Angeles County Superior Court bench, Judge Beckloff brings a wealth of experience and a deep understanding of civil, probate, and family law matters.

Key Points: 
  • I am eager to leverage my experience to facilitate constructive resolutions and uphold the integrity of the legal process at Signature Resolution."
  • "My journey from the bench to Signature Resolution marks a transition fueled by a passion for effective dispute resolution," said Judge Beckloff.
  • "We are thrilled to welcome Judge Beckloff to Signature Resolution," said Dario Higuchi, Signature Resolution founding partner and managing member.
  • In his role at Signature Resolution, Judge Beckloff aims to utilize his extensive judicial experience to facilitate fair, efficient, and effective dispute resolution.

Super Lawyers® 2024 Rising Stars Award Winner Joins Moore, Schulman & Moore, APC

Retrieved on: 
Friday, April 5, 2024
SAN, APC, Family law, University, Dean, Keen, Paternity, UCLA

SAN DIEGO, April 5, 2024 /PRNewswire/ -- Moore, Schulman & Moore, APC is excited to announce that Kimberly Keen is joining San Diego's Family Law experts. "Kimberly is a great addition to our team. Not only does her experience make her a great asset for our firm but the way she connects with clients and provides personalized service makes her a great asset for the people who trust us with their family law needs," says Moore, Schulman & Moore Founding Partner, David Schulman.

Key Points: 
  • SAN DIEGO, April 5, 2024 /PRNewswire/ -- Moore, Schulman & Moore, APC is excited to announce that Kimberly Keen is joining San Diego's Family Law experts.
  • Kimberly's legal prowess and professional achievement are recognized by Super Lawyers® 2024 with its Rising Stars award.
  • Kimberly employs a results-oriented and pragmatic approach to her cases, to limit the emotional and financial costs of protracted litigation.
  • She is committed to her community, her clients and her craft," says Moore, Schulman & Moore Founding Partner, Erik Moore.

Alation Appoints Yvonne Wassenaar to its Board of Directors

Retrieved on: 
Wednesday, March 20, 2024
VMware, WSJ, Organization, Software as a service, Growth, Specialization, Arista Networks, Business, Harvey Mudd College, University, AI, MBA, Forrester Research, Silicon, Initial public offering, Accenture, UCLA, Economics

REDWOOD CITY, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Alation, Inc. , the data intelligence company , today announced the appointment of Yvonne Wassenaar to its Board of Directors.

Key Points: 
  • REDWOOD CITY, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Alation, Inc. , the data intelligence company , today announced the appointment of Yvonne Wassenaar to its Board of Directors.
  • Wassenaar currently sits on the Board of Directors at Arista Networks, Forrester Research, JFrog, and Rubrik, and previously held key leadership positions at Accenture, Puppet, New Relic, and VMWare.
  • "My experience scaling B2B enterprise SaaS companies from $100 million to over $500 million in annual recurring revenue aligns perfectly with Alation’s growth trajectory,” said Yvonne Wassenaar .
  • Building trusted AI will only become more important over time, and I look forward to working with the board and executive team on Alation’s next phase of growth.”
    “We are thrilled to welcome Yvonne Wassenaar to our Board of Directors,” said Satyen Sangani , CEO and co-founder of Alation.